ArticleActa orthopaedica2026
The Swedish experience of capital realignment surgery for slipped capital femoral epiphysis: results from a nationwide retrospective cohort of 28 patients.
Article in Acta orthopaedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeOptimal treatment for slipped capital femoral epiphysis (SCFE) has been controversial for decades. Capital realignment surgery (predominant technique: modified Dunn) is a technique to restore anatomy, but it is associated with varying risks of avascular necrosis (AVN) of the femoral head. The aim of our study was to describe outcomes following capital realignment for severe SCFE in a nationwide cohort.
methodsA longitudinal, nationwide, retrospective cohort study of SCFE patients treated with capital realignment between 2009 and 2021 was conducted, with radiographic and clinical follow-up 2-15 years after surgery. Primary radiographic outcome was AVN. Clinical outcomes were assessed using patient-reported outcome measures (the Copenhagen Hip and Groin Outcome Score [HAGOS] and the 12-item International Hip Outcome Tool [iHOT12]).
results28 patients were included but 1 patient declined radiographic follow-up. 6/27 (22%, 95% confidence interval [CI] 11-41), developed AVN: 2/19 patients with stable SCFE and 4/8 patients with unstable SCFE. None of the 8 cases in which epiphyseal perfusion was monitored intraoperatively developed AVN. The median total HAGOS and iHOT12 scores were 77 (CI 56-94) and 76 (CI 72-88), respectively. When capital realignment was performed as primary treatment (< 1 month from diagnosis), the corresponding scores were 91 (CI 70-98) and 88 (CI 73-98).
conclusionThe overall AVN rate was 22%. Our findings suggest that capital realignment should be reserved for stable SCFE and performed as primary treatment, with intraoperative epiphyseal perfusion monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.